“Long-Term Improvements Observed in Tralokinumab-Treated Patients with Moderate-to-Severe Atopic Dermatitis: an ECZTEND Interim Analysis”, J of Skin, vol. 5, no. 6, p. s59, Nov. 2021, doi: 10.25251/skin.5.supp.59.